Form 4: Erasca GC Granted 560,000 Stock Options

Erasca, Inc.'s General Counsel and Corporate Secretary, Ebun Garner, was granted 560,000 stock options with an exercise price of $10.31, vesting over four years.

Summary

• Ebun Garner, General Counsel & Corporate Secretary of Erasca, Inc., was granted 560,000 stock options.
• The options have an exercise price of $10.31 per share.
• The grant date for these options was January 29, 2026.
• The options will expire on January 29, 2036.
• Vesting occurs monthly, with 1/48th of the shares vesting on the 29th day of each month (or the last day of February), commencing in February 2026.
• Vesting is contingent upon Ebun Garner's continuous service to Erasca, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard and generally positive corporate governance action, aligning executive incentives with long-term shareholder value. It reflects ongoing executive compensation practices.

Positives

• The grant of 560,000 stock options to a key executive like the General Counsel aligns their interests with long-term shareholder value creation.
• A 10-year expiration date provides a significant window for the executive to realize value from the options.

Negatives

• No immediate negative financial impact is apparent from this Form 4 filing, which primarily reports insider transactions.
• The exercise price of $10.31 is the current market price at the time of grant, meaning the options have no intrinsic value until the stock price rises above this level.

Risks

• The value of the stock options is entirely dependent on the future performance of Erasca, Inc.'s stock price. If the stock price does not exceed the exercise price of $10.31, the options may expire worthless.
• The vesting schedule requires continuous service, meaning the executive must remain employed by Erasca for four years to fully realize the grant.

Future Outlook

The filing indicates a long-term incentive for a key executive, suggesting a commitment to retaining talent and aligning management's interests with future company growth over the next four years (vesting period) and ten years (option life).

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the General Counsel is a standard practice in the biotechnology and pharmaceutical industries, particularly for growth-stage companies like Erasca, Inc. This compensation structure is designed to incentivize long-term performance and retention by linking executive wealth directly to shareholder value appreciation. It is a common method for attracting and retaining top talent in competitive sectors.

Comparison to Industry Standards

• StockSavvy.ai observes that a 4-year monthly vesting schedule is a common industry standard for executive equity compensation, similar to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their senior leadership.
• The grant of 560,000 options, while substantial, needs to be evaluated in the context of the company's overall outstanding shares and market capitalization to assess its relative size. For example, a similar grant at a large-cap biotech might be a smaller percentage of total outstanding shares compared to a smaller, earlier-stage company.
• The 10-year option term is also standard, providing ample time for the company's stock to appreciate, aligning with long-term drug development cycles typical in the biotech sector.

Corporate Governance

Related Party Transactions

• The stock option grant to an executive is a standard related party transaction as part of executive compensation.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased long-term value creation due to aligned executive incentives.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies.

Next Steps

• Continued monthly vesting of the stock options over the next four years, subject to continuous service.
• Potential future exercise of options by Ebun Garner if the stock price appreciates above $10.31.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event and does not provide new fundamental information about Erasca, Inc.'s operational performance or strategic direction. While it signals continued executive alignment, it does not warrant a change in investment thesis based solely on this disclosure. Investors should hold their position and await more substantive financial or operational updates.

Keywords

Erasca Inc., ERAS, Stock Option Grant, Ebun Garner, General Counsel, Insider Transaction, Form 4, Equity Compensation, Vesting Schedule